| Cat. No. |
Product Name |
Information |
| PC-20898 |
RBN3143
PARP14 inhibitor
|
RBN3143 (RBN-3143) is a potent, selective, NAD+-competitive catalytic inhibitor of PARP14 with IC50 of 4 nM, >300-fold selectivity over other ADP-ribosyltransferase (ART) family members. |
| PC-49753 |
PARP-1 inhibitor Pip6
PARP1 inhibitor
|
PARP-1 inhibitor Pip6 is an analog of PARP-1 type I inhibitor AZ0108, shows similar type I inhibition of PARP-1 but is 90-fold more cytotoxic than AZ0108. |
| PC-49687 |
Thioparib
pan-PARP inhibitor
|
Thioparib is a next-generation potent, orally bioavailable pan-PARP inhibitor with IC50 of 0.13/0.006 nM (PARP1/2), overcomes multiple PARPi resistance both in vitro and in vivo. |
| PC-49585 |
KMR-206
PARP7 inhibitor
|
KMR-206 (KMR206) is a potent, selective PARP7 inhibitor with IC50 of 13.7 nM, displays 75-fold selectivity for PARP7 over PARP2 and does not inhibit PARP1 up to 3 uM. |
| PC-49543 |
AZ3391
PARP1 inhibitor
|
AZ3391 is a blood-brain barrier permeable, subtype selective PARP-1 inhibitor. |
| PC-49520 |
RBN012759
PARP14 inhibitor
|
RBN012759 (RBN-012759) is a potent and highly selective PARP14 chemical probe inhibitor with biochemical IC50 of 3 nM in TR-FRET assays, >300-fold selectivity over all PARP family members. |
| PC-49499 |
G-631
TNKS1/2 inhibitor
|
G-631 is a potent and selective TNKS1/2 inhibitor with IC50 of 7 nM in biochemical assays of tankyrase auto-PARsylation activity, and cellular potency of 8 nM (HEK293). |
| PC-49498 |
RK-582
TNKS1/2 inhibitor
|
RK-582 (RK582) is a highly selective, potent and orally efficacious tankyrase inhibitor with IC50 of 39.1 and 36.2 nM for TNKS/TNKS2, respectively. |
| PC-49491 |
AZ1366
TNKS1/2 inhibitor
|
AZ1366 (AZ-1366) is a potent and selective inhibitor of TNSK1/2 with IC50 of 7 nM (TNKS1), also inhibits PARP1 with IC50 of 6 nM, shows Wnt pathway inhibition in DLD-1 cells (IC50<3 nM). |
| PC-49490 |
NVP-TNKS656
TNKS2 inhibitor
|
NVP-TNKS656 (TNKS656) is a highly potent, selective, and orally active tankyrase inhibitor with IC50 of 6 nM (TNKS2), 5,000-fold selectivity versus PARP1 and PARP2. |
| PC-49357 |
Mortaparib Plus
mortalin-p53 inhibitor
|
Morataprib Plus is a novel anticancer small molecule that disrupts mortalin-p53 interaction, prevents the interaction of mortalin with p53 resulting in the activation of growth arrest and apoptosis mediated by activation of p21WAF1 or BAX and PUMA signalling, respectively. |
| PC-49356 |
Mortaparib
mortalin-PARP1 inhibitor
|
Mortaparib is a dual inhibitor of mortalin-PARP1 interaction, and a p53 activating cytotoxic compound, induces activation of growth arrest and apoptosis signaling in cancer cells in vitro and in vivo. |
